177 related articles for article (PubMed ID: 24024475)
21. Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Liu-Dumlao T; Kantarjian H; Thomas DA; O'Brien S; Ravandi F
Curr Oncol Rep; 2012 Oct; 14(5):387-94. PubMed ID: 22669492
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
Tiribelli M; Sperotto A; Candoni A; Simeone E; Buttignol S; Fanin R
Leuk Res; 2009 Jan; 33(1):174-7. PubMed ID: 18471874
[TBL] [Abstract][Full Text] [Related]
23. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
Manabe A; Kawasaki H; Shimada H; Kato I; Kodama Y; Sato A; Matsumoto K; Kato K; Yabe H; Kudo K; Kato M; Saito T; Saito AM; Tsurusawa M; Horibe K
Cancer Med; 2015 May; 4(5):682-9. PubMed ID: 25641907
[TBL] [Abstract][Full Text] [Related]
24. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
[No Abstract] [Full Text] [Related]
25. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
26. Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
Kovacsovics T; Maziarz RT
Curr Oncol Rep; 2006 Sep; 8(5):343-51. PubMed ID: 16901395
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
Cai W; Liu B; Xu Y; Chen S; Sun A; He J; Shen H; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):105-9. PubMed ID: 27014978
[TBL] [Abstract][Full Text] [Related]
28. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Brandwein J
Drugs; 2007; 67(17):2655. PubMed ID: 18034600
[No Abstract] [Full Text] [Related]
29. Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Reddiconto G; Chiusolo P; Fiorini A; Farina G; Sorà F; Leone G; Sica S
Leuk Lymphoma; 2007 Oct; 48(10):2054-7. PubMed ID: 17917973
[No Abstract] [Full Text] [Related]
30. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
31. Circumventing resistance to kinase-inhibitor therapy.
Druker BJ
N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
[No Abstract] [Full Text] [Related]
32. Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Mikami T; Kato I; Oiki N; Okamoto S; Kamitori T; Tasaka K; Ogata H; Tanaka K; Umeda K; Hiramatsu H; Okamoto T; Adachi S; Takita J
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e539-e542. PubMed ID: 33843813
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
34. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
35. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.
Shimizu H; Yokohama A; Hatsumi N; Takada S; Handa H; Sakura T; Nojima Y
Eur J Haematol; 2014 Oct; 93(4):297-301. PubMed ID: 24750307
[TBL] [Abstract][Full Text] [Related]
36. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
37. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
[TBL] [Abstract][Full Text] [Related]
38. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
40. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.
Guillet S; Hirsch P; Marzac C; Mohty M; Marie JP; Legrand O
Leuk Lymphoma; 2014 Nov; 55(11):2646-8. PubMed ID: 24491028
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]